EuroEyes GmbH

EuroEyes GmbH is a specialist in refractive eye surgery, offering advanced lens treatments for various vision impairments. Their innovative procedures aim to enhance patients’ quality of life by reducing reliance on corrective eyewear. Founded in 1993 in Hamburg, Germany, EuroEyes GmbH focuses on refractive eye surgery. The company has successfully completed 2 deals, with the most recent occurring on October 14, 2019.

The CEO is Michael Zhang. EuroEyes is a leading provider of refractive eye surgery and advanced lens treatments, specializing in procedures such as Femto-LASIK, SMILE Pro, and the implantation of intraocular lenses (ICL) and multifocal lenses. Their core offerings aim to address various vision impairments, including myopia, hyperopia, astigmatism, presbyopia, and cataracts. EuroEyes employs technology to ensure precision and safety in treatments, with procedures designed to provide patients with a life free from glasses or contact lenses.

The company operates clinics across Germany, China, Denmark, and the United Kingdom, serving a diverse client base that includes individuals and healthcare professionals. Each surgical procedure is tailored to the individual's specific needs, reinforced by over 30 years of expertise within the industry. EuroEyes generates revenue through direct transactions with patients seeking eye correction procedures. The company’s transaction structure consists primarily of B2C engagements, where patients pay for surgical treatments on a per-procedure basis.

Services include specialized treatments like the implantation of multifocal lenses, which allow users to see at varying distances without corrective eyewear. Pricing reflects the advanced technology and expertise provided, including costs associated with pre-operative evaluations and post-operative care. EuroEyes also conducts informational events to educate potential patients, further driving client engagement. In October 2019, EuroEyes GmbH raised HKD 595 million in an IPO, selling 79.

33 million shares on the Main Board of The Stock Exchange of Hong Kong Limited under the ticker symbol '1846'. The company plans to utilize the proceeds from this funding to enhance its offerings and expand into new geographic regions, aiming for growth particularly within Asia and Europe.